Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Pilot Clinical Study to Evidence Safety and Efficacy of Fracture Fixation of the Distal Radius Using a Bioresorbable Bone Adhesive to Augment Metal Hardware

A prospective, multi-center (up to 4 sites), single-arm, study of 20 subjects. Patient enrollment will consist of subjects with an AO/OTA type 2R3C distal radius fracture. Enrollment will be prospectively stratified based on patient age (Stratum A: \<65 and Stratum B: ≥65 years)

Participants needed: 20
Trial details
Age: 21+Biological sex: AllType: InterventionalSponsor: RevBioUpdated: Mar 5, 2026
Eligibility criteria

Unilateral, unstable and/or displaced distal radius AO/OTA type 2R3C fracture. [+9]

Significant ligamentous disruption requiring independent repair [+13]

Status: Not yet recruiting

Safety and Effectiveness of TETRANITE Bone Adhesive for Cranial Flap Fixation Compared to Traditional Metal Hardware

The aim of this study is to demonstrate the safety and efficacy of TETRANITE, a bioresorbable bone adhesive, for Cranial Flap Fixation as compared to traditional metal hardware.

Participants needed: 204
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: RevBioUpdated: Mar 5, 2026
Eligibility criteria

Subject, and/or subject's family are able and willing to provide informed consen... [+5]

Subject has undergone a previous, open intracranial neurosurgical procedure in t... [+10]

Status: Recruiting

A Pilot Clinical Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

This clinical pilot study will evaluate the use of a bioresorbable bone adhesive to improve cranial flap fixation at two study time points (at the time of fixation and 6 months). The aim of this Pilot Study is to demonstrate the safety and efficacy of the use of Tetranite for Cranial Flap Fixation (TN-CFF) to allow clinical study of the TN-CFF device in a greater number of patients.

Participants needed: 15
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: RevBioUpdated: Mar 11, 2025Locations: 1
Eligibility criteria

Subjects can be any gender, but be between (and including) 18 and 75 years of ag... [+5]

Subject requires a procedure involving a translabyrinthine, transsphenoidal, tra... [+10]